Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
March 21 2022 - 7:00AM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of immunotherapeutic vaccines for
chronic diseases, today announced that Peter Powchik, M.D. is
joining its Board of Directors and will be retiring as Vaxxinity’s
Executive Vice President, Research & Development. This
transition will be effective March 31, 2022 and will increase the
size of the Board to seven.
“Peter is a rockstar of drug development who has contributed to
the approval of over half a dozen new drugs that help patients to
this day. We are fortunate to have him joining our Board where we
may continue to leverage his considerable expertise to develop
vaccines and treat chronic diseases,” said Lou Reese, Executive
Chairman of Vaxxinity.
“Vaxxinity is continuing to build a world-class team of
scientists and drug development experts with the drive to change
the way we treat chronic diseases, and helping to achieve our goal
of making safe, effective and affordable treatments to democratize
health,” said Dr. Peter Powchik. “We have a unique platform that
has the potential to disrupt the current treatment paradigms in
chronic diseases and allow us to rethink how medicines are
developed and delivered. By utilizing a vaccine approach, Vaxxinity
can not only provide medicines that are more affordable and
convenient, but also in combinations and stages of disease that
were previously impractical. I look forward to my next chapter with
this dynamic company.”
Prior to joining Vaxxinity and its predecessor, United
Neuroscience, Dr. Powchik was Senior Vice President, Head of
Clinical Development at Regeneron Pharmaceuticals from 2006 to
2018, where he oversaw the development of Regeneron’s first seven
approved drugs and helped to build its development and regulatory
infrastructure. Peter led the development of multiple products to
licensure including Eylea®, Kevzara®, Arcalyst®, Dupixent® and
Praluent® against PCSK9 for hypercholesterolemia. He also served
various roles in clinical development including at Chugai Pharma
USA, Novartis overseeing the development and approval of Ritalin
LA® and Focalin® and Sepracor where he initiated the development of
Lunesta®. He is a board-certified psychiatrist trained at NYU
School of Medicine, Mount Sinai Medical Center (NYC), and Columbia
University College of Physicians and Surgeons.
“We thank Peter for his outstanding contribution to Vaxxinity
and warmly welcome him to our Board of Directors,” said Mei Mei Hu,
Chief Executive Officer of Vaxxinity. “Peter has been instrumental
in defining our path and shaping our journey to create next
generation vaccines to serve the underserved around the world and
democratize health.”
About VaxxinityVaxxinity, Inc. is a
purpose-driven biotechnology company committed to democratizing
healthcare across the globe. The company is pioneering a new class
of synthetic, peptide-based immunotherapeutic vaccines aimed at
disrupting the existing treatment paradigm for chronic disease,
increasingly dominated by monoclonal antibodies, which suffer from
prohibitive costs and cumbersome administration. The company’s
proprietary technology platform has enabled the innovation of novel
pipeline candidates designed to bring the efficiency of vaccines to
the treatment of chronic diseases, including Alzheimer’s,
Parkinson’s, migraine, and hypercholesterolemia. The technology is
also implemented as part of a COVID-19 vaccine program. Vaxxinity
has optimized its pipeline to achieve a potentially historic,
global impact on human health.
For more information about Vaxxinity, Inc., visit
www.vaxxinity.com and follow us on social media @vaxxinity.
Forward-looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The use of certain words, including "believe," "may,"
“continue,” “advancing,” and "will" and similar expressions, are
intended to identify forward-looking statements. These
forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of Vaxxinity’s management about the
development of a new class of immunotherapeutic vaccines and the
innovation and efficacy of Vaxxinity’s product candidates. Various
important factors could cause actual results or events to differ
materially from those that may be expressed or implied by our
forward-looking statements. Additional important factors to be
considered in connection with forward-looking statements are
described in the "Risk Factors" section of the Company's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on December 23, 2021. The forward-looking statements are
made as of this date and Vaxxinity does not undertake any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor ContactClaudia
Styslingervaxxinity@argotpartners.com
Press ContactPhilip
Cowdellmedia@vaxxinity.com
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Sep 2023 to Sep 2024